120 related articles for article (PubMed ID: 3030847)
1. Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase.
Coughlin JP; Donahoe PK; Budzik GP; MacLaughlin DT
Mol Cell Endocrinol; 1987 Jan; 49(1):75-86. PubMed ID: 3030847
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase.
Cigarroa FG; Coughlin JP; Donahoe PK; White MF; Uitvlugt N; MacLaughlin DT
Growth Factors; 1989; 1(2):179-91. PubMed ID: 2560399
[TBL] [Abstract][Full Text] [Related]
3. Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.
Maggard MA; Catlin EA; Hudson PL; Donahoe PK; MacLaughlin DT
Metabolism; 1996 Feb; 45(2):190-5. PubMed ID: 8596488
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant mullerian inhibiting substance inhibits epidermal growth factor.
Coughlin JP; Cigarroa F; Donahoe PK; McLaughlin DT
Curr Surg; 1988; 45(3):204-5. PubMed ID: 3402255
[No Abstract] [Full Text] [Related]
6. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.
Ueno S; Manganaro TF; Donahoe PK
Endocrinology; 1988 Sep; 123(3):1652-9. PubMed ID: 2456917
[TBL] [Abstract][Full Text] [Related]
7. A possible purification of mullerian inhibiting substance and a model for its mechanism of action.
Budzik GP; Donahoe PK; Hutson JM
Prog Clin Biol Res; 1985; 171():207-23. PubMed ID: 2984697
[No Abstract] [Full Text] [Related]
8. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
[TBL] [Abstract][Full Text] [Related]
9. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation.
Lyall RM; Zilberstein A; Gazit A; Gilon C; Levitzki A; Schlessinger J
J Biol Chem; 1989 Aug; 264(24):14503-9. PubMed ID: 2788167
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation.
Laurich VM; Trbovich AM; O'Neill FH; Houk CP; Sluss PM; Payne AH; Donahoe PK; Teixeira J
Endocrinology; 2002 Sep; 143(9):3351-60. PubMed ID: 12193547
[TBL] [Abstract][Full Text] [Related]
11. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.
Yaish P; Gazit A; Gilon C; Levitzki A
Science; 1988 Nov; 242(4880):933-5. PubMed ID: 3263702
[TBL] [Abstract][Full Text] [Related]
12. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
Fuller AF; Guy S; Budzik GP; Donahoe PK
J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
[TBL] [Abstract][Full Text] [Related]
13. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
[TBL] [Abstract][Full Text] [Related]
14. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
15. Protein tyrosine phosphorylation induced by epidermal growth factor and insulin-like growth factor-I in a rat clonal dental pulp-cell line.
Kawase T; Orikasa M; Ogata S; Burns DM
Arch Oral Biol; 1995 Oct; 40(10):921-9. PubMed ID: 8526802
[TBL] [Abstract][Full Text] [Related]
16. Mullerian inhibiting substance: a fetal hormone with surgical implications.
Hutson JM; Donahoe PK; Budzik GP
Aust N Z J Surg; 1985 Dec; 55(6):599-605. PubMed ID: 2870703
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation events during Müllerian duct regression.
Hutson JM; Fallat ME; Kamagata S; Donahoe PK; Budzik GP
Science; 1984 Feb; 223(4636):586-9. PubMed ID: 6607531
[TBL] [Abstract][Full Text] [Related]
19. Epiregulin stimulates proliferation of rabbit gastric cells in primary culture through autophosphorylation of the epidermal growth factor receptor.
Sasaki E; Arakawa T; Fujiwara Y; Kawada N; Fukuda T; Higuchi K; Komurasaki T; Kobayashi K
Eur J Pharmacol; 1997 Nov; 338(3):253-8. PubMed ID: 9424019
[TBL] [Abstract][Full Text] [Related]
20. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
